Scientists work to strengthen the synergy of chemotherapy and immunotherapy against cancer – EurekAlert (press release)
EurekAlert (press release) |
Scientists work to strengthen the synergy of chemotherapy and immunotherapy against cancer
EurekAlert (press release) (April 17, 2017) – In the war on cancer, powerful chemotherapy agents are increasingly packaged with immunotherapy that primes a patient’s immune system to better battle the disease. To strengthen their synergy, scientists are now focusing on immune … |
The Hippocratic Post (blog) |
Gene Therapy Technologies, Markets and Companies Report 2017 …
GlobeNewswire (press release) Dublin, April 17, 2017 (GLOBE NEWSWIRE) — Research and Markets has announced the addition of Jain PharmaBiotech’s new report “Gene Therapy … Gene therapy for nervous system disorders – The Hippocratic PostThe Hippocratic Post (blog) |
The Hippocratic Post (blog) |
Gene Therapy Technologies, Markets and Companies Report 2017 …
Yahoo Finance Dublin, April 17, 2017– Research and Markets has announced the addition of Jain PharmaBiotech’s new report “Gene Therapy- Technologies, Markets and … Gene therapy for nervous system disorders – The Hippocratic PostThe Hippocratic Post (blog) |
Immuno-Oncology News |
Reolysin-Taxol Combo Increases Breast Cancer Patients’ Survival Rate
Immuno-Oncology News Oncolytics Biotech is partnering with other companies to develop immunotherapy and immunomodulatory applications for Reolysin, which improved breast cancer survival rates. A combination of Reolysin and the chemotherapy Taxol (paclitaxel) increased … |
Petro Global News 24 |
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with …
Yahoo Finance CRISPR Therapeutics and Casebia will have an option to exclusively license AAV vectors with desired properties for use in their in vivo gene-editing programs. StrideBio will receive development funding, milestones and royalties on licensed vectors, and … Crispr Therapeutics AG (CRSP) Given Consensus Recommendation of “Strong Buy” by AnalystsThe Cerbat Gem The Brokerages Set $25.83 Target Price for Crispr Therapeutics AG (CRSP)Petro Global News 24 Crispr Therapeutics AG (CRSP) Coverage Initiated by Analysts at Chardan CapitalBBNS Chaffey Breeze –Sports Perspectives –Community Financial News all 8 news articles » |